Edinburgh Research Explorer Highlights of the 2008 Scientific Sessions of the European Society of Cardiology Munich, Germany, August 30 to September 3, 2008

the

[1]  C. Macaya,et al.  Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. , 2009, Journal of the American College of Cardiology.

[2]  M. Mäyränpää,et al.  ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model , 2009, BMC cardiovascular disorders.

[3]  S. F. Galinski,et al.  Serum tryptase levels in acute coronary syndromes with ST elevation. , 2009, International journal of cardiology.

[4]  J. López-Sendón,et al.  Do patients with ST segment elevation myocardial infarction in Killip class I need intensive cardiac care after a successful primary percutaneous intervention? , 2009, Acute cardiac care.

[5]  Gissi-Hf Investigators.  Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[6]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[7]  J. Brugada,et al.  A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. , 2008, Heart rhythm.

[8]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[9]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[10]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[11]  R. Ferrari,et al.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.

[12]  D. J. Veldhuisen,et al.  Myocardial perfusion reserve measured with PET scan is an independent prognostic factor in patients with coronary artery disease , 2008 .

[13]  J. Ottervanger,et al.  Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial , 2008, The Lancet.

[14]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[15]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[16]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[17]  Daniel F. Schwarz,et al.  Repeated Replication and a Prospective Meta-Analysis of the Association Between Chromosome 9p21.3 and Coronary Artery Disease , 2008, Circulation.

[18]  A. Parkhomenko,et al.  Recommendations for the structure, organization, and operation of intensive cardiac care units. , 2005, European heart journal.

[19]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[20]  M. Cheitlin.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study , 2010 .

[21]  S. Nissen.  Analyses of cancer data from three ezetimibe trials. , 2009, The New England journal of medicine.

[22]  B. Gersh.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2009 .

[23]  J. Marin-Neto.  Telmisartan, ramipril, or both in patients at high risk for vascular events , 2008 .

[24]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .